ZA200705083B - Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders - Google Patents

Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders

Info

Publication number
ZA200705083B
ZA200705083B ZA200705083A ZA200705083A ZA200705083B ZA 200705083 B ZA200705083 B ZA 200705083B ZA 200705083 A ZA200705083 A ZA 200705083A ZA 200705083 A ZA200705083 A ZA 200705083A ZA 200705083 B ZA200705083 B ZA 200705083B
Authority
ZA
South Africa
Prior art keywords
agonist
prevention
treatment
neurodegenerative disorders
neurodegenerative
Prior art date
Application number
ZA200705083A
Other languages
English (en)
Inventor
Lee Erwin Schechter
Margaret Maria Zaleska
Kevin Pong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200705083B publication Critical patent/ZA200705083B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200705083A 2004-12-14 2007-06-13 Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders ZA200705083B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63576604P 2004-12-14 2004-12-14

Publications (1)

Publication Number Publication Date
ZA200705083B true ZA200705083B (en) 2010-03-31

Family

ID=36177731

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705083A ZA200705083B (en) 2004-12-14 2007-06-13 Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders

Country Status (15)

Country Link
US (1) US20060128744A1 (no)
EP (1) EP1824464A1 (no)
JP (1) JP2008523146A (no)
KR (1) KR20070088770A (no)
CN (1) CN101098683A (no)
AU (1) AU2005316675A1 (no)
BR (1) BRPI0519036A2 (no)
CA (1) CA2590841A1 (no)
CR (1) CR9200A (no)
IL (1) IL183859A0 (no)
MX (1) MX2007007206A (no)
NO (1) NO20073104L (no)
RU (1) RU2007122450A (no)
WO (1) WO2006065710A1 (no)
ZA (1) ZA200705083B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200301251A (en) * 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
JP2005305107A (ja) * 2004-03-25 2005-11-04 Sei Matsuoka 価値的情報値の測定装置およびこれを使用した測定方法
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CN104276993B (zh) * 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
CN104557664B (zh) * 2013-10-19 2020-01-21 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
UA78536C2 (en) * 2001-12-20 2007-04-10 Wyeth Corp Indolylalkylamine derivatives as ligands of 5-hydroxytryptamine-6, method of production (variants), pharmaceutical composition
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6

Also Published As

Publication number Publication date
BRPI0519036A2 (pt) 2008-12-23
EP1824464A1 (en) 2007-08-29
CN101098683A (zh) 2008-01-02
JP2008523146A (ja) 2008-07-03
KR20070088770A (ko) 2007-08-29
IL183859A0 (en) 2008-12-29
MX2007007206A (es) 2008-03-26
WO2006065710A1 (en) 2006-06-22
CR9200A (es) 2007-09-07
CA2590841A1 (en) 2006-06-22
RU2007122450A (ru) 2009-01-27
NO20073104L (no) 2007-07-02
AU2005316675A1 (en) 2006-06-22
US20060128744A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
HK1190084A1 (zh) 用於預防和治療補體相關紊亂的 多肽
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
IL230242A (en) Retinal history and methods of using them to treat visual irregularities
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL180108A0 (en) Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL181706A0 (en) The treatment of inflammatory disorders and pain
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL182574A0 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
IL187248A0 (en) Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
ZA200705083B (en) Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
EP2077838A4 (en) METHODS FOR TREATING A-RELATED DISORDERS AND COMPOSITIONS THEREFOR
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
EP1812009A4 (en) GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CNS
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
PL1727545T3 (pl) Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych
EP1776956A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENT FOR CALCIPENIA
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
EP1928473A4 (en) COMBINATION OF POLYCHITOSAMINE AND FIBRATE FOR THE PREVENTION AND TREATMENT OF HYPERLIPIDEMIA
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
GB0513413D0 (en) The treatment of inflammatory disorders and pain
ZA200704412B (en) Indenyl derivatives and use thereof for the treatment of neurological disorders